Heterogeneous interleukin-15 inducibilities in murine B16 melanoma and RM-1 prostate carcinoma by interferon-α treatment

Journal of Interferon and Cytokine Research

Volumn 29, Issue 11, 2009, Pages 719-727

  Fleischmann Jr , William Robert ^a   Wu, Tzu G ^a   Perdigão, Joana R ^a   Umhoefer, Theresa K ^a   Cao, Jade ^a   Ansari, David A ^a   Albrecht, Thomas B ^b,c   Knutson, Eugene P ^b   Rose, William A ^b   Jorgensen, Angela J ^a   Ryan, Lee M ^a   Abdalla, Linda E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; MELANOMA VACCINE; MESSENGER RNA; RECOMBINANT ALPHA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN RM 1; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LONG TERM CARE; LYMPH NODE; MACROPHAGE; MALE; MELANOMA; MELANOMA B16; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; ULTRAVIOLET RADIATION; UPREGULATION; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOMA; INTERFERON-ALPHA; INTERLEUKIN-15; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

MURINAE; MUS;

EID: 73649084051     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0073     Document Type: Article

References (21)

1. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. 1995. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52(5): 403-413.
2. Bamford RN, Battiata AP, Burton JD, Sharma H, Waldmann TA. 1996. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I R region/IL-15 fusion message that lacks many upstream AUGs that normally attenuate IL-15 mRNA translation. Proc Nat Acad Sci USA 93:2897-2902.
3. Bamford RN, DeFilippis AP, Azimi N, Kurys G, Waldmann TA. 1998. The 5' UTR, signal peptide and 3' coding sequences of IL-15 participate in its multifaceted translational control. J Immunol 160:4418-4426.
4. + T cells. J Immunol 170:5018-5026.
5. Budagian V, Bulanova E, Orinska Z, Thon L, Mamat U, Bellosta P, Basilico C, Adam D, Paus R, Bulfone-Paus S. 2004. Reverse signaling through membrane-bound interleukin-15. J Biol Chem 279:42192-42201.
6. Campbell JB, Grunberger T, Kochman MA, White SL. 1975. A microplate reduction assay for human and mouse interferon. Can J Microbiol 21:1247-1253.
7. +/CD44high T cells and its antitumor action. J Immunol 180(4):2099-2106.
8. Fidler IJ. 1973. Selection of successive tumor lines for metastasis. Nature New Biol 242:148-149.
9. Fleischmann WR Jr, Wu TG. 2004. Development of a vaccine against cancers. Med Razgl 43(suppl 5):51-61.
10. Fleischmann WR Jr, Wu TG. 2005. Development of an interferon-based cancer vaccine protocol: application to several types of murine cancers. In: Carr DJJ, ed. Methods in molecular medicine, Vol.116: Interferon Methods and Protocols. Totowa: Humana Press. pp. 151-165.
11. Grabstein KH, Eisenmann J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, Johnson L, Alderson MR, Watson JD, Anderson D, Giri JG. 1994. Cloning of a T cell growth factor that interacts with the á chain of the interleukin-2 receptor. Science 264:965-968. (Pubitemid 24196167)
12. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 T cells. Proc Natl Acad Sci USA 101:1969-1974.
13. Kramer MJ, Dennin R, Kramer C, Jones G, Connell E, Rolon N, Gruarin A, Kale R, Trown PW. 1983. Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res 3:425-435.
14. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
15. Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, Malavasi F, Ponzi AN, Paus R, Bulfone-Paus S. 1999. Human monocytes constitutively express membrane-bound, biologically active, and interferon-ã-upregulated interleukin-15. Blood 93:3531-3539.
16. Nichols JE, Niles JA, Roberts NJ Jr. 2001. Human lymphocyte apoptosis after exposure to infl uenza A virus. J Virol 73:5921-5929.
17. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, Ohta S, Tanaka M, Hara M, Kamatani N. 2002. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 14:917-924.
18. Wilkinson PC, Liew FY. 1995. Chemoattraction of human blood T lymphocytes by interleukin-15. J Exp Med 181:1255-1259.
19. Wu TY, Fleischmann WR Jr. 1998. Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-á treatment (B16á cells) as a tumor vaccine in mice. J Interferon Cytokine Res 18:829-839.
20. Wu TY, Fleischmann, WR Jr. 2001. Murine B16 melanoma vaccination- induced tumor immunity: Identification of specific immune cells and functions involved. J Interferon Cytokine Res 21:1117-1127.
21. Wu TG, Rose WA II, Albrecht TB, Knutson EP, Konig R, Perdigao JR, Nguyen AP, Fleischmann WR Jr. 2007. IFN-alpha-induced murine B16 melanoma cancer vaccine cells: induction and accumulation of cell-associated IL-15. J Interferon Cytokine Res 27(1):13-22.